Daliresp

Daliresp is a brand name of roflumilast, approved by the FDA in the following formulation(s):

DALIRESP (roflumilast - tablet; oral)

• 
  Manufacturer: FOREST RES INST INC
  
  Approval date: February 28, 2011
  
  Strength(s): 500MCG ^[RLD]

Has a generic version of Daliresp been approved?

No. There is currently no therapeutically equivalent version of Daliresp available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daliresp. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
  Patent 5,712,298
  Issued: January 27, 1998
  Inventor(s): Amschler; Hermann
  Assignee(s): BYK Gulden Lomberg Chemische Fabrik GmbH
  Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-alkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs. ##STR1##
  
  Patent expiration dates:
  
  
  • January 27, 2015
    
    ✓ 
    Patent use: TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 28, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Daliresp Consumer Information (Drugs.com)
• Daliresp Consumer Information (Wolters Kluwer)
• Daliresp Consumer Information (Cerner Multum)
• Daliresp Advanced Consumer Information (Micromedex)
• Roflumilast Consumer Information (Wolters Kluwer)
• Roflumilast Consumer Information (Cerner Multum)
• Roflumilast Advanced Consumer Information (Micromedex)